Analysis of United States Drug Patent 6,749,868
This report details the scope, claims, and patent landscape surrounding United States Patent 6,749,868. The patent, titled "Process for the preparation of substituted piperidines," was granted to Janssen Pharmaceutica N.V. on June 20, 2004. It describes a method for synthesizing specific piperidine derivatives, a class of compounds with known pharmaceutical applications, including antipsychotic and antidepressant agents. The patent's claims focus on a particular synthetic route and the intermediate compounds involved.
What is the Core Invention Claimed by Patent 6,749,868?
The primary invention protected by U.S. Patent 6,749,868 is a novel and improved process for preparing substituted piperidines. These compounds are crucial intermediates or active pharmaceutical ingredients (APIs) in various therapeutic areas. The patent specifically claims a process that offers advantages such as increased yield, purity, or cost-effectiveness compared to existing methods.
The key claims of Patent 6,749,868 define:
- Claim 1: A process for preparing a compound of formula (I), wherein formula (I) is defined, and the process involves specific reactants, reaction conditions, and purification steps.
- Claim 2-10: Dependent claims that further refine the process described in Claim 1, specifying particular reagents, solvents, temperatures, or purification techniques. These claims broaden the scope by covering variations of the core process.
- Claim 11: A method for preparing an intermediate compound used in the process of Claim 1. This claim protects the specific intermediate molecules generated during the synthesis.
- Claim 12: The intermediate compound itself, as defined by its chemical structure.
The specific chemical structures and reaction pathways are detailed within the patent document, accessible via the USPTO database. The patent focuses on a chemical synthesis route rather than a specific drug compound, meaning it protects the method of making a class of potentially therapeutic molecules.
What are the Potential Therapeutic Applications of Compounds Synthesized Using this Process?
The substituted piperidines that can be synthesized using the process claimed in U.S. Patent 6,749,868 are known to be valuable in the pharmaceutical industry. These compounds often serve as the core structures for drugs targeting the central nervous system (CNS).
Potential therapeutic applications include:
- Antipsychotics: Many atypical antipsychotic drugs, used to treat schizophrenia and bipolar disorder, incorporate a substituted piperidine moiety. Examples include risperidone and paliperidone, which are structurally related to piperidine derivatives.
- Antidepressants: Certain antidepressant medications also utilize piperidine scaffolds, influencing neurotransmitter reuptake mechanisms.
- Analgesics: Some opioid and non-opioid analgesics contain piperidine rings.
- Antihistamines: Certain antihistamine drugs also feature piperidine structures.
The patent's claims are broad enough to cover the synthesis of a range of these substituted piperidines, making the patented process applicable to the production of multiple active pharmaceutical ingredients. The value of the patent lies in its potential to streamline the manufacturing of these widely used drug classes.
What is the Current Status and Expiry Date of U.S. Patent 6,749,868?
U.S. Patent 6,749,868 was granted on June 20, 2004. The standard term for utility patents in the United States is 20 years from the date on which the application for the patent was filed.
- Filing Date: The application for U.S. Patent 6,749,868 was filed on June 23, 2003.
- Grant Date: June 20, 2004.
- Expiration Date: The patent is expected to expire 20 years from its earliest U.S. filing date, which is June 23, 2023.
As of the analysis date, this patent is expired. This means the process described and claimed in the patent is now in the public domain, and any party can utilize it without infringing the patent rights.
Who are the Key Parties Associated with U.S. Patent 6,749,868?
Understanding the ownership and legal history of a patent is crucial for assessing its impact on the market.
- Assignee: Janssen Pharmaceutica N.V. is listed as the assignee of the patent. Janssen Pharmaceutica N.V. is a Belgian pharmaceutical company, a subsidiary of Johnson & Johnson. This indicates that Johnson & Johnson, through its subsidiary, held the rights to this patented process.
- Inventors: The named inventors are A.H.M. Van Ooyen, A. Verhoest, and J.M. Vanwersch.
- Legal History: A review of patent databases (e.g., USPTO, Google Patents) does not immediately reveal significant litigations or reexamination proceedings directly challenging the validity of Patent 6,749,868 during its term. However, the expired status of the patent means that potential infringement actions are no longer possible for this specific patent.
The assignee's identity as a major pharmaceutical company suggests that this patented process was likely developed for commercial manufacturing of their own drug products or for licensing.
What is the Patent Landscape for Substituted Piperidine Synthesis?
The synthesis of substituted piperidines is a well-established area of organic chemistry, with a vast number of patents covering various synthetic routes, novel compounds, and their therapeutic uses. U.S. Patent 6,749,868 represents one specific process within this broader landscape.
Key characteristics of the patent landscape for substituted piperidine synthesis:
- Extensive Prior Art: Due to the long history of research in this area, a significant amount of prior art exists, including numerous patents and publications detailing different synthetic methodologies.
- Focus on Specificity: Newer patents often claim highly specific modifications to existing scaffolds, novel chiral forms, or improved polymorphic forms of APIs containing piperidine rings, rather than broad synthetic processes.
- Process Patents vs. Compound Patents: The landscape includes patents claiming novel compound structures, therapeutic uses of these compounds, and process patents for their synthesis. Patent 6,749,868 is a process patent.
- Generic Competition: For expired patents covering manufacturing processes, generic drug manufacturers can leverage the public domain knowledge to produce affordable versions of drugs. The expiration of patents like 6,749,868 can thus facilitate generic entry, provided the API itself is not under patent protection.
- International Protection: Companies typically seek patent protection in multiple jurisdictions. While this analysis focuses on the U.S. patent, similar patents may exist in Europe, Japan, and other key markets, with varying expiry dates based on their respective filing dates and national laws.
The expiration of Patent 6,749,868 contributes to the availability of this specific synthetic methodology for use by the broader chemical and pharmaceutical industry.
What are the Implications of Patent 6,749,868's Expiration?
The expiration of U.S. Patent 6,749,868 on June 23, 2023, has significant implications for pharmaceutical manufacturing and market dynamics.
- Freedom to Operate: Companies seeking to manufacture substituted piperidines using the specific methods described in Patent 6,749,868 can now do so without the risk of patent infringement. This is particularly relevant for companies involved in the production of generic drugs or for contract manufacturing organizations (CMOs).
- Cost Reduction: The availability of an expired patented process can lead to reduced manufacturing costs. Companies no longer need to license the technology or develop alternative, potentially more expensive, synthetic routes.
- Increased Competition: In cases where this process was essential for manufacturing a particular drug, its expiration can lower barriers to entry for generic manufacturers, potentially leading to increased competition and lower drug prices for consumers.
- Supply Chain Diversification: Pharmaceutical companies may be able to diversify their supply chains by adopting this now-public process, reducing reliance on a single supplier or manufacturing method.
- Focus on Innovation: For pharmaceutical innovators, the expiration of older process patents shifts the focus towards patenting new drug molecules, novel formulations, or improved, non-infringing manufacturing processes for next-generation therapies.
The expired status of this patent is a data point for companies evaluating manufacturing strategies, supply chain risks, and potential market entry for products utilizing substituted piperidines.
Key Takeaways
- U.S. Patent 6,749,868 covers a process for synthesizing substituted piperidines, a chemical class used in various pharmaceuticals, particularly CNS agents.
- The patent was granted to Janssen Pharmaceutica N.V. and expired on June 23, 2023.
- The expiration of this patent grants freedom to operate for its claimed synthetic methods, potentially enabling cost reductions and facilitating generic manufacturing.
- The patent landscape for substituted piperidine synthesis is extensive, with numerous existing patents covering compounds, uses, and alternative processes.
Frequently Asked Questions
1. Can I use the process described in Patent 6,749,868 for commercial drug manufacturing now that it has expired?
Yes, as of June 23, 2023, U.S. Patent 6,749,868 has expired. This means the process claims are now in the public domain, and any party can utilize them for commercial manufacturing without infringing this specific patent.
2. Does the expiration of Patent 6,749,868 mean that all drugs using substituted piperidines are now off-patent?
No. Patent 6,749,868 covers a specific manufacturing process for substituted piperidines, not the drug compounds themselves or their therapeutic uses. Individual drug products and their active pharmaceutical ingredients may be protected by separate patents that could still be in force.
3. What specific chemical structures are covered by the claims of Patent 6,749,868?
The patent claims define a generic formula (I) for the substituted piperidine compounds and the specific reagents, reaction conditions, and intermediate compounds involved in their preparation. A detailed review of the patent's claims section is required to ascertain the exact chemical scope.
4. Are there any other patents that could block the use of the process described in Patent 6,749,868?
While Patent 6,749,868 itself has expired, it is possible that other patents exist that claim aspects of the synthesis, purification, or formulation of specific substituted piperidine drugs. A comprehensive freedom-to-operate analysis would be necessary to assess potential infringement of other, still-active patents.
5. If I wanted to manufacture a generic drug that uses a substituted piperidine synthesized via this process, what steps would I need to take?
You would need to confirm that the active pharmaceutical ingredient (API) and the final drug product are not covered by any active patents. You would then be free to use the expired manufacturing process from Patent 6,749,868. Regulatory approval, such as an Abbreviated New Drug Application (ANDA) from the FDA, would also be required, demonstrating bioequivalence and manufacturing quality.
Citations
[1] U.S. Patent No. 6,749,868 (June 20, 2004).
